Press Release - March 13, 2018
Heidelberg, Germany, March 13, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on March 20, 2018, the Company will release its financial results for the quarter and year ended December 31, 2017. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, March 20, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3160515.
| United States | +1 786-789-4776 |
| Germany | +49 (0)69 2222 13420 |
| Netherlands | +31 (0) 20 721 9251 |
| Denmark | +45 35 15 80 49 |
| France | +33 (0)1 76 77 22 74 |
| Switzerland | +41 (0)22 567 5729 |
| United Kingdom | +44 (0)330 336 9105 |
An audio webcast of the conference call can be accessed in the “Events” section on the “Investors & Media” page of the Affimed website at www.affimed.com/events.php. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases.
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required, email hidden; JavaScript is required